Fifteen-year clinical experience with the Biocor porcine bioprostheses in the mitral position

Midterm Clinical Outcomes of the St Jude Medical Epic Porcine Bioprosthesis in the Mitral Position

“…The Biocor valve has been described as having good clinical results and durability. [2][3][4][5] The Epic valve has a structurally identical design to the One-and 2-year follow-up rates after surgery were 83% and 55%, respectively. On postoperative TTE, moderate or severe MR was not observed 1 year after surgery.…”

“…It is structurally identical to the St Jude Medical Biocor porcine bioprosthesis, which has a record of very long-term durability. [2][3][4][5] Moreover, the Epic valve is treated with the Linx anti-calcification process, and a pericardial shield on the outflow edge is designed to prevent abrasion. This valve is expected to perform better than the Biocor valve.…”

“…The clinical outcomes and the durability of various biological valves have been described as satisfactory. [1][2][3][4][5][6][7][8] The number of elderly people in Japan has been increasing, and in contrast to that in the past, more elderly patients have been undergoing valve replacement with a biological valve in recent years. In Japan, the number of valve replacements with a biological valve increases every year.…”

Twenty Year Patient Survival and 17 Year Complications of Isolated Mitral Biocor Standard Porcine Valve

“…Pomerantzeff [18] has reported a 15 year SVD freedom of 84.0 ± 9.8% in Brazilian patients aged 61 to 80 years at operation and of 51.8 % in patients aged 51-60. Kiraly, who operated on an exceptionally young population (mean age 48 ± 14 years), reported a 76.7% SVD freedom at 14 years [19]. We therefore think that adequacy of the prosthesis can be better estimated from the overall freedom from reoperation: Our freedom was 80.5% (actual 92%), the reoperation rate was 1.44 %/patientyears as compared to 0.9% in Mykén series, The incidence rate ratio was 1.56 (0.64-3.84), p=0.28.…”

Bioprótese Valvar Porcina: Um Legado de Mario Vrandecic

“…Após quase 40 anos de uso clínico, as evidências de seguimentos de curto, médio e longo prazos demonstram efetividade, durabilidade e segurança da referida bioprótese valvar em séries nacionais e de outros países (Tabela 1). [3][4][5][6][7][8][9][10][11][12][13][14][15][16] Em um dos seguimentos mais longos, Mykén e Bech-Hansen, avaliaram 1.712 pacientes que receberam a bioprótese Biocor porcina no Sahlgrenska University Hospital, em Gotemburgo, na Suécia, demonstrando uma sobrevida livre de mortalidade devido à falência valvar após 20 anos de 84,3% ± 6,9% e 88,0% ± 4,0%, para implantes em posições aórtica e mitral, respectivamente 16 (Tabela 1). Mario Vrandecic fundou ainda, em 1985, o Biocor Instituto, localizado em Nova Lima, região metropolitana de Belo Horizonte (MG).…”